montkqab

Property	Value
?:abstract	SUMMARY INTRODUCTION This study aims to evaluate changes in hematological parameters after the follow-up of patients who received treatment with favipiravir due to COVID-19 infections METHODS Sixty-two cases receiving favipiravir treatment for at least five days due to COVID-19 infection were evaluated retrospectively Parameters including age, gender, nasopharyngeal swab positivity, and chronic diseases were analyzed Hematologic parameters were analyzed before and after the treatment RESULTS The mean age of the patients receiving treatment with favipiravir was 63 7±12 3 years Nasopharyngeal swab positivity was detected in 67 7% The most common comorbid conditions detected in patients were hypertension in 25 cases (40 3%) and diabetes in 16 cases (25 8%) In the statistical analysis of the hematological parameters before and after treatment with favipiravir, WBC, PT-PTT-INR levels were found to be unaffected;the mean RBC was found to have decreased from 4 33 ± 0 58 M/uL to 4 16 ± 0 54 M/uL (p:0 003);the median hemoglobin level was found to have decreased from 12 3 g/dl to 11 9 g/dl (p:0 041);the hematocrit level decreased from 38 1% ± 4 8 to 36 9% ± 4 2 (p:0 026);the median neutrophil count decreased from 4 57 K/uL to 3 85 K/uL (p:0 001);the mean lymphocyte count increased from 1 22 ± 0 53 K/uL to 1 84 ± 1 19 K/uL (p:0 000);and the mean platelet count increased from 244 1 ± 85 1 K/uL to 281 9 ± 103 3 K/uL (p:0 005) CONCLUSION We concluded that the pathological effect of treatment with favipiravir on the hematologic system was the suppression in the erythrocyte series, and there were no adverse effects in other hematologic parameters RESUMO INTRODUÇÃO Este estudo tem como objetivo avaliar as alterações nos parâmetros hematológicos após o acompanhamento de pacientes que receberam tratamento com favipiravir devido à infecção por Covid-19 MÉTODOS Sessenta e dois casos em tratamento com favipiravir por pelo menos cinco dias devido à infecção por Covid-19 foram avaliados retrospectivamente Parâmetros como idade, sexo, positividade do swab nasofaríngeo e doenças crônicas foram analisados Os parâmetros hematológicos foram analisados antes e após o tratamento RESULTADOS A idade média dos pacientes que receberam tratamento com favipiravir foi de 63,7±12,3 anos A positividade do swab nasofaríngeo foi detectada em 67,7% As condições comórbidas mais comuns detectadas nos pacientes foram hipertensão em 25 casos (40,3%) e diabetes em 16 casos (25,8%) Na análise estatística dos parâmetros hematológicos antes e após o tratamento com favipiravir, os níveis de leucócitos, PT-PTT-INR não foram afetados Verificou-se que o RBC médio diminuiu de 4,33±0,58 M/uL para 4,16±0,54 M/uL (p=0,003);o nível médio de hemoglobina foi reduzido de 12,3 g/dl para 11,9 g/dl (p=0,041);o nível de hematócrito diminuiu de 38,1%±4,8 para 36,9%±4,2 (p=0,026);a contagem mediana de neutrófilos diminuiu de 4,57 K/uL para 3,85 K/uL (p=0,001);a contagem média de linfócitos aumentou de 1,22±0,53 K/uL para 1,84±1,19 K/uL (p=0,000);a contagem média de plaquetas aumentou de 244,1±85,1 K/uL para 281,9±103,3 K/uL (p=0,005) CONCLUSÃO Concluiu-se que o efeito patológico do tratamento com favipiravir no sistema hematológico foi a supressão na série eritrocitária e que não houve efeitos adversos em outros parâmetros hematológicos SUMMARY INTRODUCTION This study aims to evaluate changes in hematological parameters after the follow-up of patients who received treatment with favipiravir due to COVID-19 infections. METHODS Sixty-two cases receiving favipiravir treatment for at least five days due to COVID-19 infection were evaluated retrospectively. Parameters including age, gender, nasopharyngeal swab positivity, and chronic diseases were analyzed. Hematologic parameters were analyzed before and after the treatment. RESULTS The mean age of the patients receiving treatment with favipiravir was 63.7±12.3 years. Nasopharyngeal swab positivity was detected in 67.7%. The most common comorbid conditions detected in patients were hypertension in 25 cases (40.3%) and diabetes in 16 cases (25.8%). In the statistical analysis of the hematological parameters before and after treatment with favipiravir, WBC, PT-PTT-INR levels were found to be unaffected; the mean RBC was found to have decreased from 4.33 ± 0.58 M/uL to 4.16 ± 0.54 M/uL (p:0.003); the median hemoglobin level was found to have decreased from 12.3 g/dl to 11.9 g/dl (p:0.041); the hematocrit level decreased from 38.1% ± 4.8 to 36.9% ± 4.2 (p:0.026); the median neutrophil count decreased from 4.57 K/uL to 3.85 K/uL (p:0.001); the mean lymphocyte count increased from 1.22 ± 0.53 K/uL to 1.84 ± 1.19 K/uL (p:0.000); and the mean platelet count increased from 244.1 ± 85.1 K/uL to 281.9 ± 103.3 K/uL (p:0.005). CONCLUSION We concluded that the pathological effect of treatment with favipiravir on the hematologic system was the suppression in the erythrocyte series, and there were no adverse effects in other hematologic parameters.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/montkqab_hasAnnotation_C0879626> <https://research.tib.eu/covid-19/entity/montkqab_hasAnnotation_C3714514>
?:creator	<https://research.tib.eu/covid-19/entity/Yaylaci%2C_Sel%C3%A7uk%3B_Dheir%2C_Hamad%3B_amp%2C%3B_350%2C%3B_enocak%2C_Didar%3B_Genc%2C_Ahmed_Bilal%3B_Kocayigit%2C_Havva%3B_%C3%87eki%C3%A7%2C_Deniz%3B_Varamp%2C%3B_305%2C%3B_m%2C_Ceyhun%3B_Aydamp%2C%3B_n%2C_Abd%C3%BClkadir%3B_Koroglu%2C_Mehmet%3B_Karabay%2C_Oamp%3B_287%2C%3B_uz%2C> <https://research.tib.eu/covid-19/entity/Yaylaci%2C_Sel%C3%A7uk_Dheir_Hamad_amp_enocak_Didar_Genc_Ahmed_Bilal_Kocayigit_Havva_%C3%87eki%C3%A7_Deniz_Var_amp_m_Ceyhun_Ayd_amp_n_Abd%C3%BClkadir_Koroglu_Mehmet_Karabay_O.%3B_amp%2C_uz>
?:journal	Rev_Assoc_Med_Bras_(1992)
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/montkqab_HAS_C1138226_TREATS_C0879626>
?:source	WHO
?:title	The effects of favipiravir on hematological parameters of covıd-19 patients
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#743033 #950442
?:year	2020

Property

Value

?:abstract

SUMMARY INTRODUCTION This study aims to evaluate changes in hematological parameters after the follow-up of patients who received treatment with favipiravir due to COVID-19 infections METHODS Sixty-two cases receiving favipiravir treatment for at least five days due to COVID-19 infection were evaluated retrospectively Parameters including age, gender, nasopharyngeal swab positivity, and chronic diseases were analyzed Hematologic parameters were analyzed before and after the treatment RESULTS The mean age of the patients receiving treatment with favipiravir was 63 7±12 3 years Nasopharyngeal swab positivity was detected in 67 7% The most common comorbid conditions detected in patients were hypertension in 25 cases (40 3%) and diabetes in 16 cases (25 8%) In the statistical analysis of the hematological parameters before and after treatment with favipiravir, WBC, PT-PTT-INR levels were found to be unaffected;the mean RBC was found to have decreased from 4 33 ± 0 58 M/uL to 4 16 ± 0 54 M/uL (p:0 003);the median hemoglobin level was found to have decreased from 12 3 g/dl to 11 9 g/dl (p:0 041);the hematocrit level decreased from 38 1% ± 4 8 to 36 9% ± 4 2 (p:0 026);the median neutrophil count decreased from 4 57 K/uL to 3 85 K/uL (p:0 001);the mean lymphocyte count increased from 1 22 ± 0 53 K/uL to 1 84 ± 1 19 K/uL (p:0 000);and the mean platelet count increased from 244 1 ± 85 1 K/uL to 281 9 ± 103 3 K/uL (p:0 005) CONCLUSION We concluded that the pathological effect of treatment with favipiravir on the hematologic system was the suppression in the erythrocyte series, and there were no adverse effects in other hematologic parameters RESUMO INTRODUÇÃO Este estudo tem como objetivo avaliar as alterações nos parâmetros hematológicos após o acompanhamento de pacientes que receberam tratamento com favipiravir devido à infecção por Covid-19 MÉTODOS Sessenta e dois casos em tratamento com favipiravir por pelo menos cinco dias devido à infecção por Covid-19 foram avaliados retrospectivamente Parâmetros como idade, sexo, positividade do swab nasofaríngeo e doenças crônicas foram analisados Os parâmetros hematológicos foram analisados antes e após o tratamento RESULTADOS A idade média dos pacientes que receberam tratamento com favipiravir foi de 63,7±12,3 anos A positividade do swab nasofaríngeo foi detectada em 67,7% As condições comórbidas mais comuns detectadas nos pacientes foram hipertensão em 25 casos (40,3%) e diabetes em 16 casos (25,8%) Na análise estatística dos parâmetros hematológicos antes e após o tratamento com favipiravir, os níveis de leucócitos, PT-PTT-INR não foram afetados Verificou-se que o RBC médio diminuiu de 4,33±0,58 M/uL para 4,16±0,54 M/uL (p=0,003);o nível médio de hemoglobina foi reduzido de 12,3 g/dl para 11,9 g/dl (p=0,041);o nível de hematócrito diminuiu de 38,1%±4,8 para 36,9%±4,2 (p=0,026);a contagem mediana de neutrófilos diminuiu de 4,57 K/uL para 3,85 K/uL (p=0,001);a contagem média de linfócitos aumentou de 1,22±0,53 K/uL para 1,84±1,19 K/uL (p=0,000);a contagem média de plaquetas aumentou de 244,1±85,1 K/uL para 281,9±103,3 K/uL (p=0,005) CONCLUSÃO Concluiu-se que o efeito patológico do tratamento com favipiravir no sistema hematológico foi a supressão na série eritrocitária e que não houve efeitos adversos em outros parâmetros hematológicos
SUMMARY INTRODUCTION This study aims to evaluate changes in hematological parameters after the follow-up of patients who received treatment with favipiravir due to COVID-19 infections. METHODS Sixty-two cases receiving favipiravir treatment for at least five days due to COVID-19 infection were evaluated retrospectively. Parameters including age, gender, nasopharyngeal swab positivity, and chronic diseases were analyzed. Hematologic parameters were analyzed before and after the treatment. RESULTS The mean age of the patients receiving treatment with favipiravir was 63.7±12.3 years. Nasopharyngeal swab positivity was detected in 67.7%. The most common comorbid conditions detected in patients were hypertension in 25 cases (40.3%) and diabetes in 16 cases (25.8%). In the statistical analysis of the hematological parameters before and after treatment with favipiravir, WBC, PT-PTT-INR levels were found to be unaffected; the mean RBC was found to have decreased from 4.33 ± 0.58 M/uL to 4.16 ± 0.54 M/uL (p:0.003); the median hemoglobin level was found to have decreased from 12.3 g/dl to 11.9 g/dl (p:0.041); the hematocrit level decreased from 38.1% ± 4.8 to 36.9% ± 4.2 (p:0.026); the median neutrophil count decreased from 4.57 K/uL to 3.85 K/uL (p:0.001); the mean lymphocyte count increased from 1.22 ± 0.53 K/uL to 1.84 ± 1.19 K/uL (p:0.000); and the mean platelet count increased from 244.1 ± 85.1 K/uL to 281.9 ± 103.3 K/uL (p:0.005). CONCLUSION We concluded that the pathological effect of treatment with favipiravir on the hematologic system was the suppression in the erythrocyte series, and there were no adverse effects in other hematologic parameters.

is ?:annotates of